Jan-paul E. Bohn

Innsbruck, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

Journal: Blood advances

Published: November 12, 2025

DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.

DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.

Journal: Blood advances

Published: November 12, 2025

Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.

Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.

Journal: BMC cancer

Published: April 01, 2025

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.

Journal: Cancers

Published: February 20, 2025

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Journal: Blood

Published: January 24, 2025

Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents.

Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents.

Journal: Cancers

Published: September 23, 2024

Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.

Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.

Journal: Leukemia & lymphoma

Published: August 21, 2024

Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies.

Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies.

Journal: Frontiers in immunology

Published: January 30, 2024

Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetes.

Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetes.

Journal: Clinical kidney journal

Published: January 25, 2024

Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Journal: Current oncology reports

Published: August 10, 2023

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.

Journal: Haematologica

Published: September 04, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026